Amphastar Pharmaceuticals vs Travere Therapeutics
Amphastar Pharmaceuticals is the larger business, with $720m of revenue in fiscal 2025 against $491m for Travere Therapeutics (1.5 times as much). Travere Therapeutics grew faster (110.5% against -1.7%). Amphastar Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 13.6% against -5.2%.
| Latest fiscal year | Amphastar PharmaceuticalsAMPH, 2025 | Travere TherapeuticsTVTX, 2025 |
|---|---|---|
| Revenue | $720m | $491m |
| Revenue growth | -1.7% | 110.5% |
| Net income | $98.1m | −$25.5m |
| Operating margin | 19.5% | — |
| Net margin | 13.6% | -5.2% |
| Return on equity | 12.9% | -29.4% |
| Free cash flow | $121m | $37.8m |
| Cash | $170m | $93.0m |
| Total debt | $621m | $312m |
| Debt to equity | 78.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $75.6m | — |
| Employees | 1,976 | 497 |
| Market value | $1.15bn | $4.71bn |
| Price vs our value range | Below our value range | — |
| Moat score | 59 (Moderate) | 36 (Weak) |
| Insider trades, 12 months | 0 buys, 11 sales | 0 buys, 119 sales |